false
0001676163
0001676163
2026-11-06
2026-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
November 6, 2026
SS INNOVATIONS INTERNATIONAL, INC.
(Exact name of registrant as specified in its
charter)
| Florida |
|
001-42615 |
|
47-3478854 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
405, 3rd Floor, iLabs Info Technology Centre
Udyog Vihar, Phase III
Gurugram, Haryana India |
|
122016 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +91 73375 53469
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common Stock |
|
SSII |
|
The Nasdaq Stock Market
LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Current
Report”), the terms “SSi,” “the Company,” “we,” “us”
and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of new
Chief Financial Officer
Effective November 6, 2026, Gary G. Lo joined
the Company as its new Chief Financial Officer. Mr. Lo will be based in the United States. Mr. Lo, 56, has more than three decades of
financial and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology
businesses. Prior to joining the Company, from January 2026 to March 2026, Mr. Lo served as Chief Financial Officer of Subsense, Inc.,
a deep-technology company developing a bidirectional brain-computer interface. He previously served as Chief Financial Officer of Beyeonics
Vision, a commercial-stage medical technology company developing a fully digital microscope for ophthalmic surgery, from March 2025 to
December 2025. From January 2022 to July 2024, he served as Vice President of Finance and subsequently Chief Financial Officer of Cellares
Corporation, a cell therapy manufacturing robotics company, where he oversaw finance, accounting, investor relations, human resources,
procurement and information technology and led the company’s $255 million Series C financing in August 2023. From January 2018 to December
2021, Mr. Lo served as Vice President of Finance for Legrand’s Building Control Systems division, a global business with operations in
North America and Asia. From 2014 to 2017, he served as Vice President of Business Development (M&A) and IT at Sparta Systems, and
from 2013 to 2014, he served as Chief Financial Officer of 1WorldSync, a global cloud-based product data management company. Previously,
Mr. Lo held progressively senior finance and technology leadership positions at Johnson & Johnson from 2003 to 2013, including Finance
and IT Director for Vision Care Asia Pacific, as well as finance leadership positions at Siebel Systems from 2000 to 2003 and Boston
Scientific from 1996 to 2000. Mr. Lo began his career as a senior auditor at PwC, where he worked from 1992 to 1996. A CPA, he holds
a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting,
magna cum laude, from Boston College.
The Company and Mr. Lo entered into an
employment agreement (the “Employment Agreement”) effective November 6, 2026 (the “Effective
Date”). Mr. Lo’s employment under the Employment Agreement is at-will. The Employment Agreement provides for annual
base compensation of $400,000. Mr. Lo will be eligible for an annual cash bonus with a target amount of 50% of his base salary,
based on achievement of certain performance criteria and subject to the terms of the Employment Agreement. In addition, the
Employment Agreement provides for Mr. Lo to receive a grant of options under the Company’s 2026 Incentive Stock Plan (the
“Incentive Plan”) to purchase 500,000 shares of the Company’s common stock. The options will vest in four
annual installments commencing on the first anniversary of the Effective Date, subject to Mr. Lo’s continued employment by the
Company and the other terms and conditions of the Incentive Plan. The options will have an exercise price of $2.11 per Share (fair
market value as defined in the Incentive Plan), and will expire ten (10) years from the Effective Date. If Mr. Lo’s employment
is terminated by the Company without “Cause” (as defined in the Employment Agreement), and subject to his
execution of a release, he will be eligible for severance equal to three (3) months of base salary then in effect if the termination
occurs before the first anniversary of the Effective Date, or six (6) months of base salary then in effect if it occurs on or after
the first anniversary of the Effective Date. Mr. Lo also entered into a Confidentiality, Non-Disclosure and Assignment of Inventions
Agreement with the Company.
The above summary of the Employment Agreement
is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Current
Report and is incorporated herein by reference.
Appointment of Dr.
Vishwajyoti P. Srivastava as President
Effective November 6, 2026, the Company appointed Dr. Vishwajyoti P.
Srivastava, M.D., who had been serving as the Company’s Chief Executive Officer – Asia Pacific, as President of the Company.
In connection with his appointment, Dr. Srivastava has relocated to the United States, where he will be based in Denver, Colorado. As
President, Dr. Srivastava will oversee and coordinate the Company’s efforts to obtain regulatory approval to market its SSi Mantra
robotic surgical system in the United States and the European Union. He will also prepare the Company to enter those markets following
receipt of those approvals.
Biographical information regarding Dr. Srivastava
is set forth in under the caption “Directors, Executive Officers and Corporate Governance” in Item 10 of the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission
on March 10, 2026.
Dr. Srivastava is the son of Dr. Sudhir Srivastava,
the Company’s Chairman and Chief Executive Officer. There are no other family relationships among the Company’s executive officers
and directors.
In connection with his appointment as President and relocation, the
Board of Directors authorized an increase in Dr. Srivastava’s base salary to $500,000. The Company and Dr. Srivastava are also negotiating
the other terms of a new employment agreement, which will be disclosed in and filed as an Exhibit to a Current Report on Form 8-K, when
completed and executed.
On November 13, 2026, the Company issued a press
release announcing the appointment of Mr. Lo and the promotion of Dr. Srivastava.
A copy of the press release is included as Exhibit 99.1
to this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 10.1 |
|
Employment Agreement between SS Innovations International, Inc. and
Gary G. Lo, effective November 6, 2026+ |
| 99.1 |
|
Press Release, dated November 13, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| + |
Indicates management contract or compensatory plan
or arrangement. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 13, 2026 |
SS INNOVATIONS INTERNATIONAL, INC. |
| |
|
|
| |
By: |
/s/
Sudhir Srivastava |
| |
|
Sudhir Srivastava, M.D. |
| |
|
Chairman and Chief Executive
Officer |
Exhibit 99.1

SS Innovations Strengthens Management Team in
Preparation for Global Sales Expansion
Promotes Dr. Vishwa Srivastava to President
and Appoints Gary Lo as Chief Financial Officer
FORT
LAUDERDALE, Fla. – November 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS
Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable
and accessible to a global population, today announced the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment
of Gary Lo as Chief Financial Officer. Dr. Vishwa Srivastava previously served as the Company’s Chief Executive Officer –
Asia Pacific. Both executives are based in the United States.
Dr. Sudhir Srivastava, Chairman of the Board and
Chief Executive Officer of SS Innovations, commented, “At this critical juncture in SS Innovations’ growth journey, we are
excited to announce the promotion of Dr. Vishwa Srivastava to President of the Company and the appointment of Gary Lo as Chief Financial
Officer. Vishwa has been instrumental in the development and growth of our Asia Pacific region, and we are confident in his ability to
successfully build our US business and lead our global operations during the next phase of expansion.”
Dr. Vishwa Srivastava said, “We have established
a leading position in our immense home market of India, and I look forward to working closely with the team to build the required infrastructure
and operations to further increase the presence of our advanced, cost-effective SSi Mantra surgical robotic system in the United States
and globally in preparation for expansion. On that note, we have been responding to all queries raised by the U.S. Food and Drug Administration
during its review of our 510(k) premarket notification for the SSi Mantra and we are simultaneously continuing along the pathway toward
CE marking certification in the European Union. Additionally, we have been working at our R&D facility in India finalizing a pipeline
of future disruptive healthcare technologies that we plan to roll out in the coming months.”
Dr. Sudhir Srivastava continued, “Gary brings
to SS Innovations more than three decades of financial leadership experience and a proven track record of driving profitable growth and
value creation across a range of prominent technology companies, including in the medical technology sector. We expect to benefit from
his capital markets expertise, multinational company experience, financial planning and analysis skills, and strategic acumen as we build
a truly global organization.”
Mr. Lo said, “I am thrilled to be joining
the SSi team and supporting its mission to democratize access to advanced surgical robotic care. I believe that the SSi Mantra’s
cutting-edge surgical robotic technology, differentiated features, user-friendliness, training capabilities, proven track record of clinical
success, and cost efficiency all distinguish SS Innovations in a large and growing global market.”
About Mr. Lo
Gary Lo has more than three decades of financial
and executive leadership experience across medical technology, healthcare, robotics, enterprise software and global technology businesses.
Prior to joining the Company, Mr. Lo served as Chief Financial Officer of Subsense, Inc., a deep-technology company developing a bidirectional
brain-computer interface. He previously served as Chief Financial Officer of Beyeonics Vision, a commercial-stage medical technology company
developing a fully digital microscope for ophthalmic surgery; Vice President of Finance and subsequently Chief Financial Officer of Cellares
Corporation, a cell therapy manufacturing robotics company; Vice President of Finance for Legrand’s Building Control Systems division,
a global business with operations in North America and Asia; Vice President of Business Development (M&A) and IT at Sparta Systems;
and Chief Financial Officer of 1WorldSync, a global cloud-based product data management company.
At the start of his career, Mr. Lo held progressively
senior finance and technology leadership positions at Johnson & Johnson, finance leadership positions at Siebel Systems and Boston
Scientific, and a senior auditor role at PricewaterhouseCoopers. Mr. Lo is a licensed Certified Public Accountant (CPA). He earned a Master
of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Accounting, magna cum
laude, from Boston College.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII)
develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a
larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical
robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic
procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence
of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com
or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a modular,
multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center,
a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related information, a virtual real-time image of the robotic
patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console
is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control
functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40
different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5 mm instruments
for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K
view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different
types of surgical procedures.
Forward-Looking Statements
This press release may contain statements that
are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”
“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”
“designed,” “potential,” “forecast,” “target,” “objective,” “goal,”
or the negatives of such terms or other similar expressions identify such forward-looking statements. These statements relate to future
events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that
may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels
of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kalle.ahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
devin.sullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com